Welcome to ET Deep Dive

A Patient Finds Hope

India’s Immunotherapy Cost Crisis

 How Immunotherapy Works

Price Wall and Unsafe Workarounds

Chinese Drugs Break Through

 The Partnership Deals

Low Dose Strategies Cut Costs

Quality and Trial Evidence

Why the India China Axis Grows

 Global Scramble for Chinese Biotech

Glenmark’s Billion Dollar Bets

Beyond Oncology More Tie Ups

Closing Thoughts and Credits

A quiet revolution is underway in Indian oncology. Chinese-origin cancer drugs, brought to India through a growing number of pharma partnerships, are dramatically cutting the cost of immunotherapy — making treatment accessible to patients who previously had no options. Doctors are prescribing them, patients are responding well, and Indian companies — from Glenmark to Dr Reddy’s to Intas — are signing billion-dollar deals to expand access further. Western immunotherapy can cost up to five lakh rupees per session. Chinese-origin alternatives are bringing that down to fifty thousand. This episode explores how the India-China pharma axis is reshaping who gets treated, and how.

<p>A quiet revolution is underway in Indian oncology. Chinese-origin cancer drugs, brought to India through a growing number of pharma partnerships, are dramatically cutting the cost of immunotherapy &mdash; making treatment accessible to patients who previously had no options. Doctors are prescribing them, patients are responding well, and Indian companies &mdash; from Glenmark to Dr Reddy&rsquo;s to Intas &mdash; are signing billion-dollar deals to expand access further. Western immunotherapy can cost up to five lakh rupees per session. Chinese-origin alternatives are bringing that down to fifty thousand. This episode explores how the India-China pharma axis is reshaping who gets treated, and how.</p>

To make sense of the week’s hottest stories in business, economy, politics and markets, journalists from the Economic Times chat with reporters and industry leaders in this thrice-weekly (Tuesday, Thursday, Friday) podcast.

The Morning Brief

The Chinese Cancer Fix